Members Login
Channels
Special Offers & Promotions
Exco InTouch Wins Deloitte Technology Fast 50 Award in Recognition of Significant Growth
publication date: Nov 16, 2011
|
author/source: The Scott Partnership
Exco InTouch, the leading provider of patient
communication solutions for the pharmaceutical and healthcare sectors, today
announced that it is a winner of the 2011 Deloitte Technology Fast 50. The
awards, now in their 14th year, are an independent ranking of the 50 fastest
growing technology companies in the UK, based on percentage growth in revenue
over five years. Exco InTouch was placed as the 44th fastest growing company in
the country and the 7th fastest growing company in the South East region.
Receipt of the Fast 50 award is a significant achievement, recognising growth
based on innovation and entrepreneurship.
Exco InTouch's win comes on the back of a recent growth investment from leading growth equity and venture capital group Scottish Equity Partners (SEP).
Exco InTouch, whose clients include nine of the world's top 10 pharmaceutical businesses, offers an innovative suite of patient-focused services which are delivered using a combination of cell-phone and internet technology. Used in clinical trials, the company's services benefit both patients and pharmaceutical clients, providing patient recruitment and retention support. These unique services result in improved overall compliance and the facilitation of the electronic capture of patient reported outcomes data (ePRO) during clinical trials and in Late Phase observational studies. The business, which employs some 40 staff, has its headquarters in the UK and offices in the United States and recently opened a second UK office in Nottingham to accommodate up to 30 more staff.
With the recent £3m investment from SEP, Exco InTouch is entering its next growth phase, enabling it to invest further in people, technology and infrastructure and to further enhance its revolutionary mobile technology platform. SEP has taken a minority stake in the company. Exco InTouch will use the funds to take advantage of significant growth opportunities in the clinical trial sector, particularly in the emerging mobile patient communication market. Demand for its services is growing exponentially as pharmaceutical companies are increasingly adopting smart technology to optimise clinical trial execution.
"Making the Deloitte Technology Fast 50 is a testament to a company's commitment to technology", says Mark Doleman, Regional Partner, Deloitte UK Technology Fast 50 and Technology Fast 500 EMEA Programmes. "With its 730% growth rate over five years, Exco InTouch has proven that its leadership has the vision and determination to grow in competitive conditions."
"The Deloitte UK Technology Fast 50 is internationally recognised as being one of the most important business awards in the sector and we are thrilled to receive this accreditation", comments Tim Davis, CEO of Exco InTouch.
"Despite economic uncertainty, the past five years have proved highly successful for us, with particular growth in our ePRO and patient engagement services. We look forward to this continued growth in the future as sponsors increasingly recognise the benefits of our mobile technology in the healthcare and drug development sectors."
For further information on the Exco InTouch range of solutions, please call +44 1279 709 040 or +1 877 327 5777 or visit www.excointouch.com.
Exco InTouch's win comes on the back of a recent growth investment from leading growth equity and venture capital group Scottish Equity Partners (SEP).
Exco InTouch, whose clients include nine of the world's top 10 pharmaceutical businesses, offers an innovative suite of patient-focused services which are delivered using a combination of cell-phone and internet technology. Used in clinical trials, the company's services benefit both patients and pharmaceutical clients, providing patient recruitment and retention support. These unique services result in improved overall compliance and the facilitation of the electronic capture of patient reported outcomes data (ePRO) during clinical trials and in Late Phase observational studies. The business, which employs some 40 staff, has its headquarters in the UK and offices in the United States and recently opened a second UK office in Nottingham to accommodate up to 30 more staff.
With the recent £3m investment from SEP, Exco InTouch is entering its next growth phase, enabling it to invest further in people, technology and infrastructure and to further enhance its revolutionary mobile technology platform. SEP has taken a minority stake in the company. Exco InTouch will use the funds to take advantage of significant growth opportunities in the clinical trial sector, particularly in the emerging mobile patient communication market. Demand for its services is growing exponentially as pharmaceutical companies are increasingly adopting smart technology to optimise clinical trial execution.
"Making the Deloitte Technology Fast 50 is a testament to a company's commitment to technology", says Mark Doleman, Regional Partner, Deloitte UK Technology Fast 50 and Technology Fast 500 EMEA Programmes. "With its 730% growth rate over five years, Exco InTouch has proven that its leadership has the vision and determination to grow in competitive conditions."
"The Deloitte UK Technology Fast 50 is internationally recognised as being one of the most important business awards in the sector and we are thrilled to receive this accreditation", comments Tim Davis, CEO of Exco InTouch.
"Despite economic uncertainty, the past five years have proved highly successful for us, with particular growth in our ePRO and patient engagement services. We look forward to this continued growth in the future as sponsors increasingly recognise the benefits of our mobile technology in the healthcare and drug development sectors."
For further information on the Exco InTouch range of solutions, please call +44 1279 709 040 or +1 877 327 5777 or visit www.excointouch.com.
Media Partners